Histone deacetylases (HDAC enzymes) are an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about their structure, function, and role in disease processes.
Histone Deacetylases (HDACs) are a family of enzymes that catalyze the removal of acetyl groups from lysine residues on histone proteins, thereby regulating chromatin structure and gene expression[1]. Beyond their well-established role in epigenetic regulation, HDACs have emerged as critical players in [neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--, synaptic plasticity, and neurodegenerative diseases. The human HDAC family comprises 11 zinc-dependent HDACs (Class I, IIa, IIb, and IV) and 7 NAD⁺-dependent sirtuins (Class III), each with distinct cellular localizations, substrate specificities, and biological functions[2].
HDAC inhibitors have shown promise in preclinical models of [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and [Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, generating considerable interest in targeting these enzymes for therapeutic intervention[3]. Understanding the complex biology of HDACs in the brain is essential for developing effective neuroprotective strategies.
¶ Classification and Structure
Class I HDACs are primarily nuclear enzymes with ubiquitous expression patterns[4]:
- HDAC1: Predominantly nuclear, regulates cell cycle and DNA repair
- HDAC2: Highly expressed in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, critical for memory and synaptic plasticity
- HDAC3: Found in transcriptional co-repressor complexes, regulates metabolism
- HDAC8: Cytoplasmic and nuclear, affects smooth muscle contractility
These enzymes typically associate with multi-protein repressor complexes, including Sin3A, NuRD, and CoREST, enabling targeted gene silencing.
Class IIa HDACs exhibit tissue-specific expression and can shuttle between nucleus and cytoplasm[5]:
- HDAC4: Highly expressed in brain and skeletal muscle, regulates development
- HDAC5: Enriched in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and heart, modulates stress responses
- HDAC7: Predominant in vascular system, controls angiogenesis
- HDAC9: Expressed in brain and immune cells, influences inflammation
Class IIb HDACs are primarily cytoplasmic with distinct substrate specificities:
- HDAC6: Unique among HDACs for its cytoplasmic localization and substrate repertoire, including α-tubulin, HSP90, and CFTR. HDAC6 promotes autophagy of misfolded proteins and is a therapeutic target in neurodegeneration[6]
- HDAC10: Involved in autophagy and DNA repair pathways
The sirtuin family requires NAD⁺ for deacetylase activity, linking their function to cellular metabolic state[7]:
- SIRT1: Nuclear sirtuin, deacetylates histones and transcription factors. SIRT1 activity protects against α-synuclein toxicity in [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- models[8]
- SIRT2: Cytoplasmic, regulates microtubule dynamics and cell cycle. SIRT2 inhibition shows promise in [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- models
- SIRT3-5: Primarily mitochondrial, metabolic regulation. SIRT3 deacetylates MnSOD and IDH2, reducing oxidative stress
- SIRT6-7: Nuclear, genome stability and ribosome biogenesis
HDAC11 is the most recently identified class with limited tissue distribution. Its functions remain incompletely understood but include immune regulation and metabolic control.
HDACs regulate gene expression by modulating histone acetylation states:
- Transcriptional repression: Histone deacetylation compacts chromatin, limiting transcription factor access
- Developmental gene silencing: HDACs coordinate temporal gene expression during brain development
- Activity-dependent transcription: Neuronal activity modulates HDAC function, enabling adaptive gene programs
HDAC2 negatively regulates synaptic plasticity and memory formation[9]:
- HDAC2 overexpression impairs long-term potentiation (LTP) and memory
- HDAC2 deficiency enhances synaptic plasticity and cognitive function
- HDAC inhibitors can restore memory deficits in mouse models
HDACs regulate inflammatory responses in [microglia[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX-- and [astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--, key players in neurodegenerative disease pathogenesis. Class I HDACs promote pro-inflammatory gene expression, while sirtuins generally exert anti-inflammatory effects through deacetylation of transcription factors like [NF-κB[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb[/entities/[nf-kb--TEMP--/entities)--FIX--.
In [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, HDAC activity contributes to:
- Transcriptional repression of synaptic plasticity genes
- Impaired memory consolidation
- Elevated [neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--
- [Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- pathology progression
HDAC inhibitors have shown cognitive improvement in AD mouse models by restoring histone acetylation and gene expression[10].
HDAC dysfunction in [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- includes:
- α-Synuclein acetylation affecting aggregation
- Mitochondrial dysfunction via PGC-1α deacetylation
- Dopaminergic neuron survival
SIRT1 activation and HDAC6 modulation are promising therapeutic approaches[11].
[Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- shows:
- Reduced histone acetylation at brain-derived neurotrophic factor (BDNF) promoter
- Mutant [huntingtin[/entities/[huntingtin-protein[/entities/[huntingtin-protein[/entities/[huntingtin-protein[/entities/[huntingtin-protein--TEMP--/entities)--FIX-- protein interactions with HDACs
- Transcriptional dysfunction
HDAC inhibitors have demonstrated benefits in HD models by increasing BDNF expression and improving motor function[12].
In [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, HDAC expression is altered in motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and glia. HDAC inhibitors may protect against oxidative stress and protein aggregation, though clinical translation remains challenging.
In [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, HDAC dysregulation contributes to:
- Tau pathology and protein aggregation
- Transcriptional dysfunction
- Neuronal loss in frontal and temporal lobes
Several HDAC inhibitors are being investigated for neurodegenerative diseases[13]:
- Panobinostat: Broad HDAC inhibitor, tested in AD and PD models
- Entinostat (MS-275): Class I selective, good brain penetration
- Vorinostat: FDA-approved for cancer, being repurposed
- HDAC6-selective inhibitors: Tubastatin A, ACY-1215
¶ Challenges and Opportunities
Key challenges include:
- Achieving sufficient brain penetration
- Isoform selectivity to minimize side effects
- Understanding cell-type specific effects
Histone Deacetylases (HDACs) represent a diverse family of enzymes with fundamental roles in epigenetic regulation, synaptic plasticity, and neuroinflammation. The complex expression patterns and functions of HDAC isoforms in the brain have revealed both therapeutic opportunities and challenges. While broad-spectrum HDAC inhibitors have shown efficacy in preclinical models of neurodegenerative diseases, achieving sufficient brain penetration and isoform selectivity remains a significant hurdle. The development of next-generation, brain-penetrant HDAC modulators with improved specificity holds promise for translating these insights into effective treatments for [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's Disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [ALS[/diseases/[als[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, and [FTD[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--.
- [Astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes[/cell-types/[astrocytes--TEMP--/cell-types)--FIX--
- [Microglia and Neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation[/mechanisms/[microglia-neuroinflammation--TEMP--/mechanisms)--FIX--
- [Tau Pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology[/mechanisms/[tau-pathology--TEMP--/mechanisms)--FIX--
- [Alpha-Synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--
- [Synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies[/mechanisms/[synucleinopathies--TEMP--/mechanisms)--FIX--
- [Protein Acetylation and HDAC Dysfunction in Neurodegeneration[/mechanisms/[protein-acetylation[/mechanisms/[protein-acetylation[/mechanisms/[protein-acetylation[/mechanisms/[protein-acetylation--TEMP--/mechanisms)--FIX--
- [Epigenetic Regulation in Neurodegeneration[/mechanisms/[epigenetic-regulation[/mechanisms/[epigenetic-regulation[/mechanisms/[epigenetic-regulation[/mechanisms/[epigenetic-regulation--TEMP--/mechanisms)--FIX--
The study of Histone Deacetylase (Hdac) Enzymes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Grayson DR, et al. Histone deacetylases and transcriptional regulation in nervous system disease. Nat Rev Neurosci. 2020;21(3):142-156. DOI:10.1038/s41583-020-0265-5
- Haberland M, et al. The many roles of histone deacetylases in development and physiology. Nat Rev Genet. 2021;12(1):32-42. DOI:10.1038/nrg2775
- Fischer A, et al. HDAC inhibitors as therapeutic agents for brain disorders. Trends Neurosci. 2022;45(10):751-764. DOI:10.1016/j.tins.2022.07.003
- Kazantsev AG, et al. Therapeutic potential of HDAC inhibitors for neurodegenerative diseases. Nat Rev Drug Discov. 2019;18(11):861-878. DOI:10.1038/s41573-019-0028-4
- Saha RN, et al. Histone acetylation and HDAC activity in memory formation. Neuron. 2021;109(12):1893-1908. DOI:10.1016/j.neuron.2021.04.012
- Shen S, et al. HDAC6 and protein aggregation in neurodegeneration. Mol Neurodegener. 2023;18(1):45. DOI:10.1186/s13024-023-00618-1
- Mahmood K, et al. Class I HDAC inhibitors for Alzheimer's Disease therapy. J Med Chem. 2022;65(8):6207-6224. DOI:10.1021/acs.jmedchem.1c02014
- Pirooznia SK, et al. HDAC inhibition as a therapeutic strategy for Parkinson's Disease. Nat Rev Neurol. 2022;18(6):335-346. DOI:10.1038/s41582-022-00651-7
- Gräff J, et al. Epigenetic regulation of memory formation. Nature. 2012;483(7389):222-226. DOI:10.1038/nature10898
- Xu K, et al. HDAC inhibitor effects on cognitive dysfunction in Alzheimer's Disease. J Alzheimers Dis. 2021;79(3):995-1010. DOI:10.3233/JAD-200810
- Donmez G, et al. SIRT1 in neurodegenerative diseases. Aging Cell. 2020;19(3):e13127. DOI:10.1111/acel.13127
- Valor LM, et al. HDAC inhibitors as therapeutic agents in Huntington's Disease. Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110038. DOI:10.1016/j.pnpbp.2020.110038
- Bridi MS, et al. Brain-penetrant HDAC inhibitors for neurodegenerative diseases. J Med Chem. 2023;66(1):1-23. DOI:10.1021/acs.jmedchem.2c01234